Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
N/A
1(25.0%)
4Total
Phase 2(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT01009034Completed

Concentrations of Maraviroc in the Semen of HIV-Infected Men

Role: lead

NCT01045265Completed

Concentrations of Raltegravir in the Semen of HIV-Infected Men

Role: lead

NCT01613157Completed

Predictors of Antiretroviral Pharmacokinetics in HIV-infected Women With Virologic Suppression

Role: lead

NCT00520897Phase 2Completed

Integrase Inhibitor (MK-0518) Viral Decay

Role: lead

NCT00334022Not ApplicableCompleted

Fuzeon Viral Decay Pilot Study

Role: lead

NCT00333892Completed

Leukapheresis to Obtain Lymphocytes for Studies on Antiretroviral Naive HIV-infected Patients

Role: lead

NCT00333736Phase 2Completed

Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon Administration

Role: lead

NCT00333684Phase 2Completed

Safety, Efficacy and Psychological Effects of Treating Antiretroviral Drug-Induced Facial Lipoatrophy With Bio-Alcamid

Role: lead

All 8 trials loaded